Vaccine company Valneva SE (Nasdaq:VALN) (Euronext Paris:VLA) and and the Coalition for Epidemic Preparedness Innovations (CEPI) announced on Monday that CEPI has awarded Valneva an additional USD41.3m to expand access to IXCHIQ, the world's first chikungunya vaccine.
This funding will support broader access to the vaccine in low- and middle-income countries, as well as post-marketing trials and potential label extensions in children, adolescents and pregnant women.
CEPI will provide the funds to Valneva over the next five years, with support from the European Union's Horizon Europe programme.
The project will help generate additional data to potentially support extended IXCHIQ labels in chikungunya-endemic countries and vulnerable populations at risk of being infected with the disease.
Chikungunya virus (CHIKV) is a mosquito-borne viral disease spread by the bites of infected Aedes mosquitoes which causes fever, severe joint pain, muscle pain, headache, nausea, fatigue and rash.
Eisai forecasts 73% Leqembi revenue growth in FY 2025, boosting BioArctic royalties
ValiRx subsidiary Inaphaea extends drug repurposing deal with Dominion Biotech
Lilly declares Q2 2025 dividend
Bruker acquires majority stake in RECIPE to expand clinical mass spectrometry diagnostics
Emmaus Life Sciences reports drop in revenues, increased loss in 2024
L'Oréal and WHO Foundation partner to expand global skin health access
Valneva to supply IXCHIQ vaccine for chikungunya outbreak in La Réunion
ANI Pharmaceuticals announces buyout of royalty obligation for ILUVIEN and YUTIQ
Sirum collaborates with Governor Wes Moore to expand medication access across Maryland